Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (21-30 of 117) with videos related to

Pageof 12
Sort By:
Blood|July 20, 2023
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cellsPhilipp Karschnia, Kevin C Miller, Andrew J Yee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 2023
Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapyHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
Hematological Oncology|October 5, 2023
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphomaHazim S Ababneh, Andrea K Ng, Jeremy S Abramson, et al.
Haematologica|June 15, 2023
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapyHazim S Ababneh, Andrea K Ng, Matthew J Frigault, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2020
Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future DirectionsEric A Meyerowitz, Pritha Sen, Sara R Schoenfeld, et al.
Transplantation and Cellular Therapy|February 15, 2025
Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T CellsFrederick L Locke, Zahra Mahmoudjafari, Partow Kebriaei, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 25, 2020
Acute Kidney Injury After the CAR-T Therapy TisagenlecleucelMeghan D Lee, Ian A Strohbehn, Harish S Seethapathy, et al.
Blood Advances|April 9, 2025
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myelomaJoshua N Gustine, Andrew R Branagan, Diana D Cirstea, et al.
Transplantation and Cellular Therapy|March 13, 2026
Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell TherapyKatherine J Liu, Lingxiao Zhang, Baijun Zhou, et al.
Circulation|November 25, 2024
Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell TherapyOsnat Itzhaki Ben Zadok, Panagiotis Simitsis, Caron Jacobson, et al.
Pageof 12

Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
Blood|July 20, 2023
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cellsPhilipp Karschnia, Kevin C Miller, Andrew J Yee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 2023
Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapyHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
Hematological Oncology|October 5, 2023
Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphomaHazim S Ababneh, Andrea K Ng, Jeremy S Abramson, et al.
Haematologica|June 15, 2023
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapyHazim S Ababneh, Andrea K Ng, Matthew J Frigault, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2020
Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future DirectionsEric A Meyerowitz, Pritha Sen, Sara R Schoenfeld, et al.
Transplantation and Cellular Therapy|February 15, 2025
Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T CellsFrederick L Locke, Zahra Mahmoudjafari, Partow Kebriaei, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 25, 2020
Acute Kidney Injury After the CAR-T Therapy TisagenlecleucelMeghan D Lee, Ian A Strohbehn, Harish S Seethapathy, et al.
Blood Advances|April 9, 2025
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myelomaJoshua N Gustine, Andrew R Branagan, Diana D Cirstea, et al.
Transplantation and Cellular Therapy|March 13, 2026
Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell TherapyKatherine J Liu, Lingxiao Zhang, Baijun Zhou, et al.
Circulation|November 25, 2024
Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell TherapyOsnat Itzhaki Ben Zadok, Panagiotis Simitsis, Caron Jacobson, et al.
Pageof 12